Hydroxyethyl starch - Can the safety problems be ignored?

Wiener Klinische Wochenschrift

Volumn 116, Issue 17-18, 2004, Pages 583-594

  Wiedermann, Christian J ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

Anaphylaxis; Hemorrhage; Hydroxyethyl starch; Kidney failure; Pruritus; Safety

Indexed keywords

ADRENALIN; ALBUMIN; AMINOPHYLLINE; CORTICOSTEROID; DOPAMINE; EPHEDRINE; HETASTARCH; RANITIDINE;

ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING DISORDER; BRADYCARDIA; BRONCHOSPASM; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; EDEMA; ERYTHEMA; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER FAILURE; MOLECULAR WEIGHT; POLYNEUROPATHY; PORTAL HYPERTENSION; PRURITUS; REVIEW; TACHYCARDIA; TACHYPNEA; THORAX PAIN; URTICARIA; VISUAL DISORDER;

ADULT; AGE FACTORS; AGED; ANAPHYLAXIS; BLOOD COAGULATION DISORDERS; BLOOD VISCOSITY; CESAREAN SECTION; COLLOIDS; CROSS-OVER STUDIES; FEMALE; GELATIN; HEMORRHAGE; HEMOSTASIS; HETASTARCH; HUMANS; INCIDENCE; INFANT, NEWBORN; KIDNEY; KIDNEY FAILURE; MALE; MOLECULAR WEIGHT; PILOT PROJECTS; PLASMA SUBSTITUTES; PREGNANCY; PRURITUS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SAFETY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 5344227584     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-004-0237-3     Document Type: Review

References (130)

1. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al (2001) Effects of hydroxyethyl-starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357: 911-916
2. Wilkes MM, Navickis RJ, Sibbald WJ (2001) Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 72: 527-533
3. Morgan PW, Berridge JC (2000) Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. Br J Anaesth 85: 696-699
4. Ring J, Messmer K (1977) Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1: 466-469
5. Laxenaire MC, Charpentier C, Feldman L (1994) Reaction anaphylactoides aux substitutes colloidaux du plasma: incidence, facteurs de risqué, mécanismes. Enquete prospective multicentrique francaise. Ann Fr Anest Reanim 13: 301-310
6. Solanke TF (1968) Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander). Br Med J 3: 783-785
7. Boon JC, Jesch F, Ring J, Messmer K (1976) Intravascular persistence of hydroxyethyl starch in man. Eur Surg Res 8: 497-503
8. Thompson WL (1980) Hydroxyethyl starch. Dev Biol Stand 48: 259-266
9. Jung F, Koscielny J, Mrowietz C, Förster H, Schimetta W, Kiesewetter H, et al (1993) Einfluß der Molekülstruktur von Hydroxyä thylstärke auf die Eliminationskinetik und die Fließfähigkeit des Blutes bei Probanden. Arzneimittelforschung 43: 99-105
10. Boldt J (2004) Hydroxyethylstärke (HES). Wien Klin Wochenschr 116: 159-169
11. Mishler JM IV (1980) Pharmakokinetik mittelmolekularer Hydroxyäthylstärke (HÄS 200/0,5). Infusionsther Klin Ernähr 7: 96-102
12. Köhler H, Zschiedrich H, Linfante A, Appel F, Pitz H, Glasen R (1982) Die Elimination von Hydroxyäthylstärke 200/0,5, Dextran 40 und Oxypolygelatine. Klin Wochenschr 60: 293-301
13. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH (2004) Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs RD 5: 1-9
14. Asskali F, Lehmann G, Förster H (2002) Thrombelastographische Gerrinnungsanalyse nach in-vitro- und in-vivo-Hämodilution mit Hydroxyethylstärke (HES). Anästhesiol Intensivmed Notfallmed Schmerzther 37: 258-266
15. Kasper SM, Stromich A, Kampe S, Radbruch L (2001) Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation. J Clin Anesth 13: 486-490
16. Ickx BE, Bepperling F, Melot C, Schulman C, van der Linden PJ (2003) Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution. Br J Anaesth 91: 196-202
17. Mishler JM, Parry ES, Sutherland BA, Bushrod JR (1979) A clinical study of low molecular weight-hydroxyethyl starch, a new plasma expander. Br J Clin Pharmacol 7: 619-622
18. Behne M, Thomas H, Bremerich DH, Lischke V, Asskali F, Forster H (1998) The pharmacokinetics of acetyl starch as a plasma volume expander in patients undergoing elective surgery. Anesth Analg 86: 856-860
19. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron JF (1998) Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/ 0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 16: 151-160
20. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF (2002) The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 95: 544-551
21. Kumle B, Boldt J, Piper S, Schmidt C, Suttner S, Salopek S (1999) The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Analg 89: 1124-1130
22. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C (2003) Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 29: 763-769
23. Dehne MG, Muhling J, Sablotzki A, Papke G, Kuntzsch U, Hempelmann G (1997) Einfluß von Hydroxyethylstärke-Lösung auf die Nierenfunktion bei operativen Intensivpatienten. Anästhesiol Intensivmed Notfallmed Schmerzther 32: 348-354
24. Deman A, Peelers P, Sennesael J (1999) Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial Transplant 14: 1517-1520
25. Winkelmayer WC, Glynn RJ, Levin R, Avorn J (2003) Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 64: 1046-1049
26. Riou B, Cittanova ML (1999) An international review of HES. Intensive Care Med 25: 1340-1341
27. Waldhausen P, Kiesewetter H, Leipnitz G, Scielny J, Jung F, Bambauer R, et al (1991) Durch Hydroxyäthylstärke induzierte passagere Niereninsuffizienz bei vorbestehender gloumerulärer Schädigung. Acta Med Austriaca 18 [Suppl 1]: 52-55
28. Boldt J, Knothe C, Schindler E, Hammermann H, Dapper F, Hempelmann G (1993) Volume replacement with hydroxyethyl starch solution in children. Br J Anaesth 70: 661-665
29. Dehne MG, Sablotzki A, Muhling J, Papke G, Kuntzsch U, Hempelmann G (1998) Akutes Nierenversagen: non-invasive Frühdiagnostik des akuten Nierenversagens bei operativen Intensivepatienten. Anaesthesist 47: 193-201
30. Wiedermann CJ (2004) Renal impairment in cardiac surgery patients receiving hydroxyethyl starch. Intensive Care Med 30: 519-520; author reply 521
31. Himpe D, van Cauwelaert P, Neels H, Stinkens D, van den Fonteyne F, Theunissen W, et al (1991) Priming solutions for cardiopulmonary bypass: comparison of three colloids. J Cardiothorac Vasc Anesth 5: 457-466
32. Liet JM, Bellouin AS, Boscher C, Lejus C, Roze JC (2003) Plasma volume expansion by medium molecular weight hydroxyethyl starch in neonates: a pilot study. Pediatr Crit Care Med 4: 305-307
33. Veldman A, Fischer D (2004) Is hydroxyethyl starch safe in neonates? Pediatr Crit Care Med 5: 202-203; author reply 203
34. Dehne MG, Muhling J, Sablotzki A, Dehne K, Sucke N, Hempelmann G (2001) Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment. J Clin Anesth 13: 103-111
35. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R (2003) Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 96: 1453-1459
36. Winkelmayer WC, Avorn J (2004) Stable creatinine clearance using large-dose HES versus reduced GFR. Kidney Int 65: 1111-1112
37. Egli GA, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR (1997) Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. Br J Anaesth 78: 684-689
38. Konrad C, Markl T, Schuepfer G, Gerber H, Tschopp M (1999) The effects of in vitro hemodilution with gelatin, hydroxyethyl starch, and lactated Ringer's solution on markers of coagulation: an analysis using SONOCLOT. Anesth Analg 88: 483-488
39. de Jonge E, Levi M (2001) Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 29: 1261-1267
40. Huraux C, Ankri AA, Eyraud D, Sevin O, Menegaux F, Coriat P, et al (2001) Hemostatic changes in patients receiving hydroxyethyl starch: the influence of ABO blood group. Anesth Analg 92: 1396-1401
41. Jonville-Bera AP, Autret-Leca E, Gruel Y (2001) Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 345: 622-623
42. Heilmann L, Lorch E, Hojnacki B, Muntefering H, Forster H (1991) Die Speicherung von zwei unterschiedlichen Hydroxyäthylstärke- Präparaten in der Plazenta nach Hämodilution bei Patientinnen mit fetaler Mangelentwicklung oder Schwangerschaftshochdruck. Infusionstherapie 18: 236-243
43. Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT, et al (1995) HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 74: 1452-1456
44. Deusch E, Gamsjäger T, Kress HG, Kozek-Langenecker SA (2003) Binding of hydroxyethyl starch molecules to the platelet surface. Anesth Analg 97: 680-683
45. Keyser EJ, Latter DA, Morin JE, Murshid AA, Denis F, de Varennes B (1999) Pentastarch versus albumin in cardiopulmonary bypass prime: impact on blood loss. J Card Surg 14: 279-286
46. Vogt NH, Bothner U, Lerch G, Lindner KH, Georgieff M (1996) Large-dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 83: 262-268
47. Omar MN, Shouk TA, Khaleq MA (1999) Activity of blood coagulation and fibrinolysis during and after hydroxyethyl starch (HES) colloidal volume replacement. Clin Biochem 32: 269-274
48. Kapiotis S, Quehenberger P, Eichler HG, Schwarzinger I, Partan C, Schneider B, et al (1994) Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: comparison with albumin. Crit Care Med 22: 606-612
49. Niemi TT, Kuitunen AH (1998) Hydroxyethyl starch impairs in vitro coagulation. Acta Anaesthesiol Scand 42: 1104-1109
50. de Jonge E, Levi M, Buller HR, Berends F, Kesecioglu J (2001) Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med 27: 1825-1829
51. Boldt J, Müller M, Mentges D, Papsdorf M, Hempelmann G (1998) Volume therapy in the critically ill: is there a difference? Intensive Care Med 24: 28-36
52. Mortelmans YJ, Vermaut G, Verbruggen AM, Arnout JM, Vermylen J, Van Aken H, et al (1995) Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth Analg 81: 1235-1242
53. Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, et al (2002) The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 95: 858-865
54. van der Linden PJ, de Hert SG, Daper A, Trenchant A, Schmartz D, Defrance P, et al (2004) 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients. Can J Anaesth 51: 236-241
55. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F (2001) Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vase Anesth 15: 316-321
56. Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A (2001) The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery. Anesth Analg 92: 565-571
57. Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, et al (2002) The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: an in vitro study using Thrombelastograph® coagulation analysis (ROTEG®). Anesth Analg 94: 1280-1287
58. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR (1998) Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg 87: 989-993
59. Boldt J, Lehmann A, Rompert R, Haisch G, Isgro F (2000) Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Vase Anesth 14: 264-268
60. Gallandat Huet RCG, Siemens AW, Baus D, van Rooyen-Butijn WT, Haagenaars JAM, van Oeveren W, et al (2000) A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 47: 1207-1215
61. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P (2001) Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 92: 855-862
62. Kasper SM, Meinert P, Kampe S, Gorg C, Geisen C, Mehlhorn U, et al (2003) Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 99: 42-47
63. Tabuchi N, de Haan J, Gallandat Huet RC, Boonstra PW, van Oeveren W (1995) Gelatin use impairs platelet adhesion during cardiac surgery. Thromb Haemost 74: 1447-1451
64. Tigchelaar I, Gallandat Huet RC, Korsten J, Boonstra PW, van Oeveren W (1997) Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Eur J Cardiothorac Surg 11: 626-632
65. Tigchelaar I, Gallandat Huet RC, Boonstra PW, van Oeveren W (1998) Comparison of three plasma expanders used as priming fluids in cardiopulmonary bypass patients. Perfusion 13: 297-303
66. Treib J, Haass A, Pindur G, Grauer MT, Treib W, Wenzel E, et al (1996) Influence of low and medium molecular weight hydroxyethyl starch on platelets during a long-term hemodilution in patients with cerebrovascular diseases. Arzneimittelforschung 46: 1064-1066
67. Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K (1996) Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 56: 168-172
68. Entholzner EK, Mielke LL, Calatzis AN, Feyh J, Hipp R, Hargasser SR (2000) Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand 44: 1116-1121
69. Konrad CJ, Markl TJ, Schuepfer GK, Schmeck J, Gerber HR (2000) In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT. Anesth Analg 90: 274-279
70. Franz A, Braunlich P, Gamsjager T, Felfernig M, Gustorff B, Kozek-Langenecker SA (2001) The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 92: 1402-1407
71. Felfernig M, Franz A, Bräunlich P, Fohringer C, Kozek-Langenecker SA (2003) The effects of hydroxyethyl starch solutions on thromboelastography in preoperative male patients. Acta Anaesthesiol Scand 47: 70-73
72. Boldt J, Haisch G, Suttner S, Kumle B, Schellhaass A (2002) Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend®) on measures of coagulation. Br J Anaesth 89: 722-728
73. Jamnicki M, Bombeli T, Seifert B, Zollinger A, Camenzind V, Pasch T, et al (2000) Low- and medium-molecular-weight hydroxyethyl starches: comparison of their effect on blood coagulation. Anesthesiology 93: 1231-1237
74. Petroianu GA, Liu J, Maleck WH, Mattinger C, Bergler WF (2000) The effect of in vitro hemodilution with gelatin, dextran, hydroxyethyl starch, or Ringer's solution on Thrombelastograph. Anesth Analg 90: 795-800
75. Standl T, Burmeister MA, Schroeder F, Currlin E, Schulte am Esch J, Freitag M (2003) Hydroxyethyl starch (HES) 130/0.4 provides larger and faster increases in tissue oxygen tension in comparison with prehemodilution values than HES 70/0.5 or HES 200/0.5 in volunteers undergoing acute normovolemic hemodilution. Anesth Analg 96: 936-943
76. Kuitunen AH, Hynynen MJ, Vahtera E, Salmenpera MT (2004) Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. Anesth Analg 98: 291-297
77. Rudolf J (2002) Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 14: 33-41
78. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W (1999) Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 82: 510-515
79. Jurecka W, Szepfalusi Z, Parth E, Schimetta W, Gebhart W, Scheiner O, et al (1993) Hydroxyethylstarch deposits in human skin - a model for pruritus? Arch Dermatol Res 285: 13-19
80. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA (1997) Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 136: 553-559
81. Paulini K, Sonntag W (1976) Veränderungen des RHS der Ratte nach parenteraler Gabe von Dextran (Mw 40000) und Hydroxyäthylstärke (Mw 40000): Chemische, licht- und elektronenmikroskopische Untersuchungen. Infusionstherapie 3: 294-299
82. Ständer S, Szépfalusi Z, Bohle B, Ständer H, Kraft D, Luger TA, et al (2001) Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study. Cell Tissue Res 304: 261-269
83. Ständer S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, et al (2002) Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 310: 279-287
84. Dettori N, Spahn DR (2003) Hydroxyethyl starches and pruritus: a real problem? TATM 5: 401-404
85. Roeser B, Tronnier H (1990) Zur Pathogenese von HAES-Nebenwirkungen an der Haut. Z Haut Geschlechtskr 157: 986-987
86. Celik I, Duda D, Stinner B, Kimura K, Gajek H, Lorenz W (2003) Early and late histamine release induced by albumin, hetastarch and polygeline: some unexpected findings. Inflamm Res 52: 408-416
87. Lorenz W, Duda D, Dick W, Sitter H, Doenicke A, Black A, et al (1994) Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Trial Group Mainz/Marburg. Lancet 343: 933-940
88. Waitzinger J, Bepperling F, Pabst G, Opitz J (2003) Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs RD 4: 149-157
89. Asskali F, Förster H (1999) Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetitiver Infusion bei gesunden Versuchspersonen. Anästhesiol Intensivmed Notfallmed Schmerzther 34: 537-541
90. Pfeifer U, Kult J, Forster H (1984) Ascites als Komplikation hepatischer Speicherung von Hydroxyethylstärke (HES) bei Langzeitdialyse. Klin Wochenschr 62: 862-866
91. Dienes HP, Gerharz CD, Wagner R, Weber M, John HD (1986) Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension. J Hepatol 3: 223-227
92. Christidis C, Mal F, Ramos J, Senejoux A, Callard P, Navarro R, et al (2001) Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 35: 726-732
93. Auwerda JJ, Wilson JH, Sonneveld P (2002) Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 137: 1013-1014
94. Förster H, Wicarkzyk C, Dudziak R (1981) Bestimmung der Plasmaelimination von Hydroxyaethylstärke und von Dextran mittels verbesserter analytischer Methodik. Infusionsther Klin Ernähr 2: 88-94
95. Köhler H, Kirch W, Vogt J, Höffler D (1977) Pharmakokinetik von Hydroxyäthylstärke bei Niereninsuffizienz. Verh Dtsch Ges Inn Med 83: 1676-1678
96. Bode U, Deisseroth AB (1981) Donor toxicity in granulocyte collections: association of liehen planus with the use of hydroxyethyl starch leukapheresis. Transfusion 21: 83-85
97. Parker NE, Porter JB, Williams HJ, Leftley N (1982) Pruritus after administration of hetastarch. Br Med J (Clin Res Ed) 284: 385-386
98. Boldt J (2003) New light on intravascular volume replacement regimens: what did we learn from the past three years? Anesth Analg 97: 1595-1604
99. Dieterich HJ (2003) Recent developments in European colloid solutions. J Trauma 54: S26-30
100. Treib J, Baron JF, Grauer MT, Strauss RG (1999) An international view of hydroxyethyl starches. Intensive Care Med 25: 258-268
101. Sharland C, Huggett A, Nielson MS, Friedmann PS (1999) Persistent pruritus after pentastarch infusions in intensive care patients. Anaesthesia 54: 500-501
102. Grauer MT, Baus D, Woessner R, Bepperling F, Kahles T, Georgi S, et al (2001) Effects on general safety and coagulation after long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 in patients with acute ischemie stroke. Results of a randomized, placebo-controlled, double-blind study. Crit Care 5 [Suppl 1]: S53-54
103. Kimme P, Jannsen B, Ledin T, Gupta A, Vegfors M (2001) High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions. Acta Anaesthesiol Scand 45: 686-689
104. Murphy M, Carmichael AJ, Lawler PG, White M, Cox NH (2001) The incidence of hydroxyethyl starch-associated pruritus. Br J Dermatol 144: 973-976
105. Barron ME, Wilkes MM, Navickis RJ (2004) A systematic review of the comparative safety of colloids. Arch Surg 139: 552-563
106. Grundmann T, Gramer L (1993) Pruritus bei Infusions-therapie mit Hydroxyethylstärke verschiedener Menge. Wehrmed Mschr 2: 47-48
107. Desloovere C, Knecht R (1995) Infusionstherapie bei Hörsturz: Reduktion des Juckreizrisikos nach Hydroxyethylstärke (HES) unter Erhalt des Therapieerfolges - eine prospektive randomisierte Studie. Laryngorhinootologie 74: 468-472
108. Gall H, Kaufmann R, von Ehr M, Schumann K, Sterry W (1993) Persistierender Pruritus nach Hydroxyäthylstärke-Infusionen: retrospektive Langzeitstudie an 266 Fällen. Hautarzt 44: 713-716
109. Szeimies RM, Stolz W, Wlotzke U, Korting HC, Landthaler M (1994) Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. Br J Dermatol 131: 380-382
110. Leunig A, Szeimies RM, Wilmes E, Gutmann R, Stolz W, Feyh J (1995) Klinische und elektronenmikroskopische Untersuchung zur Hörsturztherapie mit der Kombination 10% HES 200/0,5 und Pentoxifyllin. Laryngorhinootologie 74: 135-140
111. Speight EL, MacSween RM, Stevens A (1997) Persistent itching due to etherified starch plasma expander. BMJ 314: 1466-1467
112. Klein RE, Mogollon G (1984) Erythema multiforme following the infusion of hydroxyethyl starch. Transfusion 24: 166-167
113. Weisshaar E, Stander S, Metze D, Diepgen TL (2004) Hydroxyethylstä rke- (HES-) induzierter Pruritus als sekundäre Folge eines Arbeitsunfalls. Hautarzt May 13: 1-6
114. Albegger K, Schneeberger R, Franke V, Oberascher G, Miller K (1992) Juckreiz nach Therapie mit Hydroxyäthylstärke (HES) bei otoneurologischen Erkrankungen. Wien Med Wochenschr 142: 1-7
115. Bothner U, Georgieff M, Vogt NH (1998) Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/ 0.5) solution: a randomized, controlled epidemiology study. Anesth Analg 86: 850-855
116. Gröchenig E, Albegger K, Dieterich HJ, Franke RP, Gerlach E, Jurecka W, et al (1998) Hydroxylethylstarch-related pruritus: a prospective multicentre investigation of 544 patients. Perfusion 11: 62-69
117. Dieterich HJ, Kraft D, Sirtl C, Laubenthal H, Schimetta W, Polz W, et al (1998) Hydroxyethyl starch antibodies in humans: incidence and clinical relevance. Anesth Analg 86: 1123-1126
118. Kreimeier U, Christ F, Kraft D, Lauterjung L, Niklas M, Peter K, et al (1995) Anaphylaxis due to hydroxyethyl-starch-reactive antibodies. Lancet 346: 49-50
119. Dutcher JP, Aisner J, Hogge DE, Schiffer CA (1984) Donor reaction to hydroxyethyl starch during granulocytapheresis. Transfusion 24: 66-67
120. Cullen MJ, Singer M (1990) Severe anaphylactoid reaction to hydroxyethyl starch. Anaesthesia 45: 1041-1042
121. McHugh GJ (1998) Anaphylactoid reaction to pentastarch. Can J Anaesth 45: 270-272
122. Kannan S, Milligan KR (1999) Moderately severe anaphylactoid reaction to pentastarch (200/0.5) in a patient with acute severe asthma. Intensive Care Med 25: 220-222
123. Ebo DG, Schuerwegh A, Stevens WJ (2000) Anaphylaxis to starch. Allergy 55: 1098-1099
124. Vercauteren MP, Coppejans HC, Sermeus L (2003) Anaphylactoid reaction to hydroxyethylstarch during cesarean delivery in a patient with HELLP syndrome. Anesth Analg 96: 859-861
125. Kreimeier U, Messmer K (2002) Small-volume resuscitation with hypertonic sodium colloid solution - what does clinical routine tell us? Wien Klin Wochenschr 114: 76-77
126. Schimetta W, Schochl H, Kroll W, Polz W, Polz G, Mauritz W (2002) Safety of hypertonic hyperoncotic solutions - a survey from Austria. Wien Klin Wochenschr 114: 89-95
127. Hemodilution in Stroke Study Group (1989) Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. Stroke 20: 317-323
128. Mast H, Marx P (1991) Neurological deterioration under isovolemic hemodilution with hydroxyethyl starch in acute cerebral ischemia. Stroke 22: 680-683
129. Veneman TF, Nijhuis JO, Woittiez AJJ (2004) Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial. Wien Klin Wochenschr 116: 305-309
130. Groeneveld ABJ (2004) Why albumin may still work. Wien Klin Wochenschr 116: 283-285